Figure 3
Figure 3. CD115lo and CD115hi subsets of GMP-Ly6C+ cells are enriched for GPs and MPs, respectively. (A) CD115 expression by GMP-Ly6Cāˆ’ and GMP-Ly6C+ cells was assessed by flow cytometry. (B-C) One hundred thousand CD115lo and CD115hi cells isolated from the GMP-Ly6C+ subset of CD45.2 donor mice by FACS were injected IV into CD45.1 recipient mice (nonirradiated) on day 0. Spleens were harvested from recipient mice on days 3 and 4, and splenocytes were enriched for CD45.2+ (donor-derived) cells by depleting CD45.1+ cells prior to staining to detect donor cell-derived (CD45.2+) neutrophils (green gates), monocytes, and macrophages (blue gates) by flow cytometry (see supplemental Figure 4 for gating strategy). CD45.2+CD11b+ splenic cells are shown. Data presented are from 1 experiment that is representative of at least 3 independent experiments. (D) Summary of surface marker expression by oligopotent GMPs and lineage-committed GPs and MPs.

CD115lo and CD115hi subsets of GMP-Ly6C+ cells are enriched for GPs and MPs, respectively. (A) CD115 expression by GMP-Ly6Cāˆ’ and GMP-Ly6C+ cells was assessed by flow cytometry. (B-C) One hundred thousand CD115lo and CD115hi cells isolated from the GMP-Ly6C+ subset of CD45.2 donor mice by FACS were injected IV into CD45.1 recipient mice (nonirradiated) on day 0. Spleens were harvested from recipient mice on days 3 and 4, and splenocytes were enriched for CD45.2+ (donor-derived) cells by depleting CD45.1+ cells prior to staining to detect donor cell-derived (CD45.2+) neutrophils (green gates), monocytes, and macrophages (blue gates) by flow cytometry (see supplemental Figure 4 for gating strategy). CD45.2+CD11b+ splenic cells are shown. Data presented are from 1 experiment that is representative of at least 3 independent experiments. (D) Summary of surface marker expression by oligopotent GMPs and lineage-committed GPs and MPs.

Close Modal

or Create an Account

Close Modal
Close Modal